

REMARKS

The Examiner requires restriction of pending claims 1-101 under 35 U.S.C. § 121, between the following patentably distinct species of inventions:

- A) Antibody;
- B) CD40 ligand;
- C) CD40;
- D) nonprotein;
- E) library of known agents;
- F) modified from a known agent;
- G) small molecule.

Applicants elect the Species A (antibodies), with traverse, for substantive examination in this application. The claims reading on species A include claims: 1-13, 21-23, 25-29, 38-56, 65-69, 75, 78-97 and 98-101.

The Examiner also requires applicants to elect one of the following patentably distinct species of indications:

- (A) arthritis;
- (B) scleroderma;
- (C) fibrosis;
- (D) atherosclerosis;
- (E) reperfusion injury;
- (F) allograft rejection, organ rejection;
- (G) multiple sclerosis;
- (H) vasculitis;
- (I) psoriasis; or
- (J) myeloma.

Application No. 10/618,298  
Reply dated January 8, 2007  
Reply to July 7, 2006 Restriction Requirement

In response, applicants elect species (H): vasculitis. The claims reading on this species include claims: 1-78, 92-93 and 95-96.

Applicants make the foregoing elections expressly without waiver of their rights: (1) to file for and obtain claims directed to non-elected subject matter in one or more patent applications claiming priority herefrom under 35 U.S.C. § 120 and (2) subject to allowance of a generic claim, to rejoin other claims depending therefrom or otherwise including all the limitations of the allowable generic claim.

Applicants request favorable consideration and allowance of this application.

Respectfully submitted,

  
\_\_\_\_\_  
Margaret A. Pierri (Reg. No. 30,709)  
Stanley D. Liang (Reg. No. 43,753)  
Attorneys for Applicants  
FISH & NEAVE IP GROUP  
ROPES & GRAY LLP  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000  
Fax: (212) 596-9090